Reply to Shields et al.: Electronic Cigarettes and the Lung Proteome.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

1. E-cigarette use and respiratory disorders: an integrative review of converging evidence from epidemiological and laboratory studies.The European respiratory journal · 2021
   Pooled it
2. Current Insights on the Impact of Proteomics in Respiratory Allergies.International journal of molecular sciences · 2022
   Review

Corrections and comments

• Comment on
  Chronic E-Cigarette Exposure Alters the Human Bronchial Epithelial Proteome.2018
• Comment on
  Electronic Cigarettes and the Lung Proteome.2018

Authors and funding

3 authors at 1 institution in 1 country.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as